Efek Hook pada Prolaktinoma: Tantangan Diagnosis pada Remaja dengan Galaktorea dan Amenore

Authors

  • Fara Julyta Aliyah Universitas Syiah Kuala
  • Rijal Bulqini Universitas Syiah Kuala

DOI:

https://doi.org/10.55606/jurrike.v5i1.8379

Keywords:

Amenorrhea, Dopamine Agonists, Galactorrhea, Hook Effect, Prolactinoma

Abstract

Prolactinoma is the most common functional pituitary adenoma, particularly in adolescent females, and is typically characterized by amenorrhea and galactorrhea resulting from hyperprolactinemia. However, in certain cases, serum prolactin levels may appear normal due to the hook effect, an immunoassay measurement error caused by extremely high prolactin concentrations that interfere with antigen–antibody complex formation. We report the case of a 17-year-old female presenting with a five-month history of galactorrhea, accompanied by breast pain, headache, and primary amenorrhea. Brain MRI revealed a pituitary mass measuring 1.4 × 0.8 × 0.5 cm, suspicious for prolactinoma, while serum prolactin was within the normal range (17.33 ng/mL). The discrepancy between clinical manifestations, lesion size, and laboratory findings raised suspicion of the hook effect. The patient was treated with dopamine agonists, bromocriptine and cabergoline, and referred for multidisciplinary management involving endocrinology, neurosurgery, and obstetrics–gynecology. Despite the absence of prolactin dilution testing, MRI findings supported the diagnosis of prolactinoma, and the patient demonstrated a favorable clinical response to therapy. This case highlights the importance of recognizing laboratory variability, performing comprehensive hormonal evaluation, and considering prolactin dilution assays when clinical and laboratory findings are discordant, particularly in adolescent patients with suggestive symptoms.

Downloads

Download data is not yet available.

References

Araújo, C., Marques, O., Almeida, R., & Santos, M. J. (2018). Macroprolactinomas: Longitudinal assessment of biochemical and imaging therapeutic responses. Endocrine, 62, 470–476. https://doi.org/10.1007/s12020-018-1703-4

Cho, K. R., Jo, K. I., & Shin, H. J. (2013). Bromocriptine therapy for the treatment of invasive prolactinoma: The single institute experience. Brain Tumor Research and Treatment, 1(2), 71–77. https://doi.org/10.14791/btrt.2013.1.2.71

Colao, A., & Pirchio, R. (2021). Pituitary tumors in childhood. In K. R. Feingold, S. F. Ahmed, & B. Anawalt (Eds.), Endotext. MDText.com. https://www.ncbi.nlm.nih.gov/books/NBK279057/

Fisher, J. N. (2017). The pituitary gland and pituitary adenomas in childhood. Pediatric Clinics of North America, 64(3), 543–555.

Frieze, T. W., Mong, D. P., & Koops, M. K. (2002). Hook effect in prolactinomas: Case report and review of literature. Endocrine Practice, 8(4), 296–303. https://doi.org/10.4158/EP.8.4.296

Gayatri, N. P. A. D., & Hidayati, H. B. (2020). Laporan kasus: Perbaikan kadar prolaktin pada makroadenoma hipofisis dengan terapi bromokriptin dan EETA. Jurnal Farmasi Klinik Indonesia, 9(3), 237–244. https://doi.org/10.15416/ijcp.2020.9.3.237

Glezer, A., & Bronstein, M. D. (2015). Prolactinomas. Endocrinology and Metabolism Clinics of North America, 44(1), 71–78. https://doi.org/10.1016/j.ecl.2014.11.003

Gonçalves, R. F., Vaz, M. A. S., Rollin, G., & Rassier, I. G. (2023). The hook effect: A case study of a giant invasive prolactinoma with falsely low serum prolactin. Cureus, 15(9). https://doi.org/10.7759/cureus.46194

Gunatilake, S. B., & Sinha, S. (2020). Amenorrhea in adolescence: A practical approach. Obstetrics, Gynaecology & Reproductive Medicine, 22(1), 7–17.

Iglesias, P., & Díez, J. J. (2013). Macroprolactinoma: A diagnostic and therapeutic update. QJM: An International Journal of Medicine, 106(6), 495–504. https://doi.org/10.1093/qjmed/hcs240

Kars, M., Dekkers, O. M., Pereira, A. M., & Romijn, J. A. (2010). Update in prolactinomas. Netherlands Journal of Medicine, 68(3), 104–112.

Lopes, M. B. S. (2020). The 2017 World Health Organization classification of tumors of the pituitary gland: A summary. Acta Neuropathologica, 139(6), 821–832.

Melmed, S., Casanueva, F. F., & Hoffman, A. R. (2022). Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 107(7), 1713–1736.

Raverot, V., Perrin, P., Chanson, P., Jouanneau, E., Brue, T., & Raverot, G. (2022). Prolactin immunoassay: Does the high-dose hook effect still exist? Pituitary, 25(4), 653–657. https://doi.org/10.1007/s11102-022-01246-8

Tirosh, A., & Shimon, I. (2021). Prolactinomas in adolescents and young adults: Current perspectives. Neuroendocrinology, 111(1), 20–28.

Witek, P., & Zielinski, G. (2021). Dopamine agonists in the treatment of hyperprolactinemia and prolactinomas: A review. Endokrynologia Polska, 72(2), 152–162.

Yatavelli, R. K. R. (2023). Prolactinoma. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK459347/

Yildirim, A. E., Divanoglu, D., & Nacar, O. A. (2020). Galactorrhea in adolescents: A rare but important clinical finding. Journal of Pediatric and Adolescent Gynecology, 33(3), 310–313.

Yoon, J. H., Kim, S. W., & Kim, S. H. (2021). Clinical, hormonal, and neuroradiological characteristics and therapeutic outcomes of prolactinomas in children and adolescents. Frontiers in Endocrinology, 12.

Downloads

Published

2026-02-09

How to Cite

Fara Julyta Aliyah, & Rijal Bulqini. (2026). Efek Hook pada Prolaktinoma: Tantangan Diagnosis pada Remaja dengan Galaktorea dan Amenore. JURNAL RISET RUMPUN ILMU KEDOKTERAN, 5(1), 402–410. https://doi.org/10.55606/jurrike.v5i1.8379